Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingTargeting gastrointestinal stromal tumors: the role of regorafenibRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsFOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotypingPharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.The preclinical development of regorafenib for the treatment of colorectal cancer.Renal effects of targeted anticancer therapies.Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathySmall molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.Topical administration of regorafenib eye drops: Phase I dose-escalation study in healthy volunteers.Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry.Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogsRole of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q23923997-4DE74D21-957B-4F56-AC95-81E4D98CECE8Q26747162-6A6993DE-D94D-4097-A5C9-A1474D74E682Q26851417-AA2F7F6E-22A6-44A8-9C37-DA20200273E1Q34583743-D1534FD9-0462-446B-A486-0E2EA9ED4D77Q36177646-897DD0EF-4548-4F2B-BCE7-4234401B067CQ37687310-732B014D-1CCA-414C-943C-D485B365C8CBQ38217516-03A2C18D-5EA6-4308-8435-ABC9F4B467E8Q38367168-B98500D5-1AF1-4F2D-8B42-F4ECA7ED6C50Q41525644-714A2242-3FF1-46C8-8D24-D3D774FFD31CQ42290443-E0C49722-A085-4D23-9AB1-6EBC9124F8D3Q47123875-3B50C58F-18B8-4CA2-8E1A-EE33B29AC2CAQ50119662-D18EEB70-444C-4684-A3D7-F090C1ED23E5Q55071596-4EF81A37-71AD-45D6-B460-71ABF6668D98Q56763239-A46F189E-2D6B-4384-BF2E-6AF523031F96Q58788266-D06D575F-7D93-4C88-8D6B-FD140B9781BA
P2860
Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Regorafenib: a novel multitarg ...... strointestinal stromal tumors.
@en
type
label
Regorafenib: a novel multitarg ...... strointestinal stromal tumors.
@en
prefLabel
Regorafenib: a novel multitarg ...... strointestinal stromal tumors.
@en
P2860
P356
P1476
Regorafenib: a novel multitarg ...... strointestinal stromal tumors.
@en
P2093
Christine M Walko
Meredith D Keisler
P2860
P304
P356
10.1177/1060028013509792
P407
P50
P577
2013-11-01T00:00:00Z